One lowcap I've been finding pretty interesting today, and one that's been getting mentioned by a few KOLs, is $ALOIS

I'll say upfront that this one is a bit of a gamble, but I genuinely like the idea behind it, and the R/R looks pretty decent at the right entry. It might actually be one of the lowcaps with the clearest narratives I've come across today

Basically, $ALOIS is an AI agent built to research Alzheimer's disease

What caught my attention is that the team isn't just selling another AI concept. They already have a live product at agentalois.com, using real human brain data to generate and test research hypotheses

According to the project, the system has already tested thousands of predictions, publicly documented failed results, and identified some interesting findings, including SPRY4

Another catalyst I'm watching is Alzheimer's Challenge, a global competition announced by Prima Mente on October 8, focused on discovering new AI-driven treatment hypotheses for Alzheimer's

$ALOIS is being presented as a project participating in this challenge. Top teams could get their hypotheses tested in actual wet labs. However, the competition isn't expected to officially begin until spring 2027, so this is still a longer-term catalyst

The team also recently claimed around 115 SOL in creator fees and said they plan to use those funds to cover compute costs and support further research

From a trading perspective, attention is still relatively limited, while the chart has been moving sideways for quite some time. I think $ALOIS could attract more capital if the team keeps delivering meaningful updates and the narrative starts gaining traction

My trading plan :

I'll start with a small position first and see how price reacts

> Safer entry: Wait for a dip around $300K–$400K MC

> Stop-loss: Cut if MC drops below $200K

Personally, I like the R/R here, but it's still a gamble, so I'm not planning to size in too heavily

I also think this narrative needs a little more time to sink in, at least until tomorrow, to see what the team delivers next and how the community responds

Overall, this is mainly a bet on what the team is building and whether the AI x biotech narrative can continue attracting attention

2Dx7XJQp2LGdq14nP98swmtUhfhHz8FVs98bt11Mpump

DYOR